2022年10月6日

Genmab A/S丹麥哥本哈根大股東公告;2022年10月5日消息——Genmab A/S(納斯達克代碼:GMAB)根據丹麥資本市場法第30條宣布，惠靈頓管理集團LLP已通知我們，截至2022年10月4日，惠靈頓管理集團LLP通過股份和金融工具持有Genmab A/S 3,309,527股投票權，占Genmab A/S股本和投票權的5.03%。Genmab是一家國際生物技術公司，其核心宗旨是改善癌症患者的生活。20多年來，Genmab轉變癌症治療的願景推動其充滿激情、創新和協作的團隊發明了下一代抗體技術平台，利用轉化研究和數據科學，促進了多種不同的癌症治療，對人們的生活產生了影響。為了為患者開發和提供新療法，Genmab與生物技術和製藥公司建立了20多個戰略合作夥伴關係。Genmab的專利管道包括雙特異性t細胞接合物，下一代免疫檢查點調節劑，效應功能增強抗體和抗體-藥物偶聯物。Genmab總部位於丹麥哥本哈根，在荷蘭烏得勒支、美國普林斯頓、新澤西州和日本東京設有辦事處。欲了解更多信息，請訪問Genmab.com並關注我們的網站Twitter.com/Genmab。聯係電話:+1 609 524 0065;E: mmp@genmab.com安德魯·卡爾森，副總裁，投資者關係主管T: +45 3377 9558; E: acn@genmab.com This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products or technologies obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com and the risk factors included in Genmab’s most recent Annual Report on Form 20-F and other filings with the U.S. Securities and Exchange Commission (SEC), which are available at www.sec.gov . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements to reflect subsequent events or circumstances after the date made or in relation to actual results, unless required by law. Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®; HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®; HexaBody in combination with the HexaBody logo®; DuoHexaBody® and HexElect®.